Abstract:e14542 Background: Immunosuppressive factors in the tumor microenvironment reduce the therapeutic efficacy of cancer vaccines; therefore, dampening the tumor immunosuppressive environment while activating antitumor immunity should be a useful approach for cancer therapy. Cancer-associated fibroblasts (CAFs) are among the most important cellular components of the tumor microenvironment and play an important role in the development and progression of tumors. Fibroblast activation protein α (FAPα) is a type II transmembrane protein specifically expressed by CAFs in most epithelial cancers. Gene sequence homology between human and murine FAPα is 90%. Heterogeneity of genes in the evolution of the formation of such nuances can be utilized to break immune tolerance, enhance immunogenicity, induce tumour cell autoimmune responses and thus inhibit tumor growth. Methods: Tumor cells were transfected with human FAPα plasmids employing the cationic lipid DOTAP. Its antitumor effects were investigated in three established tumor models. The potential immune mechanisms were investigated through adoptive immunotherapy and 51Cr release assay. The distributions of the immune cells in the tumor microenvironment were detected by immunohistochemical staining and flow cytometry. Results: Our results shown that whole tumor cell vaccine expressing human FAPα significantly inhibit tumor growth and prolong the survival of tumor bearing mice. This antitumor immune response was involved both of cellular and humoral immune responses. FAPα specific neutralizing antibodies were found in the serum of vaccinated mice and CAFs were significantly reduced within the tumors. Furthermore, this vaccine enhanced the infiltration of CD4+ T cells and CD8+ T cells, and suppressed the accumulation of immunosuppressive cells in the tumor microenvironment. Conclusions: These findings suggest that whole tumor cell vaccine expressing human FAPα inhibit tumor growth by producing FAPα specific neutralizing antibodies and CTLs, and targeting tumor cells and CAFs. These observations provide a new strategy for the clinical use of genetically modified tumor cells as cancer vaccines.

Immunotherapy Targeting Fibroblast Activation Protein Inhibits Tumor Growth And Increases Survival In A Murine Colon Cancer Model

Antitumor Effect of a Whole Tumor Cell Vaccine Expressing Human Fibroblast Activation Protein in Murine Tumor Models.

The application of the fibroblast activation protein α-targeted immunotherapy strategy

Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model

Enhancement of Fibroblast Activation Protein Α-Based Vaccines and Adenovirus Boost Immunity by Cyclophosphamide Through Inhibiting IL-10 Expression in 4T1 Tumor Bearing Mice.

Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein α by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model.

Improvement of Anti-Tumor Immunity of Fibroblast Activation Protein Α Based Vaccines by Combination with Cyclophosphamide in a Murine Model of Breast Cancer.

A DNA Vaccine Expressing an Optimized Secreted FAPα Induces Enhanced Anti-Tumor Activity by Altering the Tumor Microenvironment in a Murine Model of Breast Cancer

A Whole Cell Tumor Vaccine Expressing Human Fibroblast Activation Protein Α Targets Cancer Cells and Cancer-Associated Fibroblasts

Fibroblast Activation Protein α and Targeted Therapy of Tumor

Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody-Drug Conjugate Targeting Fibroblast Activation Protein

Epitope-based minigene vaccine targeting fibroblast activation protein α induces specific immune responses and anti-tumor effects in 4 T1 murine breast cancer model

Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice

Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-α and Heme Oxygenase-1

Anti-tumour effects of a xenogeneic fibroblast activation protein-based whole cell tumour vaccine in murine tumour models

Effect of Short Hairpin RNA Targeting of Fibroblast Activation Protein on Tumor Growth and Angiogenesis in a 4T1 Murine Breast Cancer Model.

Abstract B025: A T cell engager targeting cancer associated fibroblasts inhibits tumor growth and modulates the tumor microenvironment

From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment

Short hairpin RNA targeting of fibroblast activation protein inhibits tumor growth and improves the tumor microenvironment in a mouse model

Fibroblast Activation Protein-α as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review

Immunotherapy of Tumor with Vaccine Based on Basic Fibroblast Growth Factor-Activated Fibroblasts